Vixiar Medical, Inc., a privately held Maryland company dedicated to the development of non-invasive devices and systems for monitoring cardiopulmonary diseases, announced today that it has raised seed round financing of over $1.5 million.

Proceeds will be used to complete regulatory submissions and fund final engineering and initial production of the Company’s first product, Indicor™, a non-invasive point of care monitoring technology for estimating cardiac filling pressure. The investment group includes representation from Asia, Europe and the US, with local investors including the Abell Foundation, and Maryland’s TEDCO.

“We are excited to receive the support of this group of local and global investors and move forward to achieve our critical milestones including commercialization of our first technology,” said Kevin Thibodeau, Vixiar CEO. “Heart failure is a growing global healthcare challenge and we are eager to offer clinicians a non-invasive, cost-effective solution for identifying early signs so they can intervene earlier and avoid costly hospitalizations.”

About Vixiar Medical™

Vixiar Medical, Inc., develops non-invasive, cost-effective devices and systems for monitoring cardiopulmonary diseases, particularly those with significant clinical and economic burden. The Company’s first product, Indicor™, is a handheld point of care device and digital platform for monitoring worsening heart failure. Headquartered in Annapolis, Maryland, the Company is a spinout of Johns Hopkins. For more information, go to http://www.vixiar.com.